Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body, and its symptoms range from general malaise to serious, CNS and renal manifestations…
Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength, which can place a considerable burden on healthcare systems. A significant unmet need exists for…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different systems and organs of the body and manifest with a wide spectrum of clinical symptoms. Lupus nephritis (LN) is…
In the atopic dermatitis market, topical therapies have been the mainstay of treatment, especially for patients with a mild to moderate form of the disease. Conventional systemic immunosuppressants…
The atopic dermatitis (AD) market is poised to undergo a revolution owing to recent advances in understanding of disease pathology, the recent approval of topical crisaborole (Pfizer’s Eucrisa)…
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that usually affects children but can persist or start in adulthood. For many years, the treatment landscape has remained…
AD is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard AD treatments aim to protect the skin barrier through…
The revolution in genomic sciences has spurred significant drug development in rare diseases, approximately 80% of which have a genetic etiology. The field of gene-based therapies, while still in…
The diabetic nephropathy (DN) market is poised to expand rapidly over the next decade as late-stage therapies reach the G7 markets. These agents represent the first potential disease-modifying…
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist for renal anemia, physicians, patients, and healthcare systems are concerned over some…
The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…
Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. Because of the role of the kidney in many of the…
Systemic lupus erythematosus (SLE) is a complex disease characterized by distinct manifestations. Currently, most treatments available to treat SLE are used off-label. The approval of Benlysta in…
Patients with osteoporosis and osteopenia are at increased risk of suffering fractures. These fractures place a considerable burden on public health systems, and significant unmet need remains in…
Market Outlook: Many cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are…